Close Menu

Mark Stapley

Marc Stapley plans to leave Illumina, effective Jan 1., 2019. Stapley is currently executive VP of strategy and corporate development at Illumina, where he is responsible for corporate strategy, corporate and business development, and infrastructure. He joined Illumina in 2012 and has held multiple roles with the firm, including as CFO and chief administrative officer. Prior to joining Illumina, he was senior VP of finance at Pfizer.


Jim Mullen

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.